NDAINJECTIONINJECTABLE
Approved
Feb 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
BUMEX (bumetanide) by Bausch Health is clinical pharmacology bumex is a loop diuretic with a rapid onset and short duration of action. First approved in 1983.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUMEX (bumetanide) is a potent loop diuretic with rapid onset and short duration of action, approximately 40 times more potent than furosemide on a mg-for-mg basis. It acts primarily on the ascending limb of the loop of Henle to inhibit sodium and chloride reabsorption, with a secondary proximal tubule effect. BUMEX is indicated for management of edema and fluid overload in conditions such as congestive heart failure, liver cirrhosis, and renal disease.
LOE Approaching
Product is in LOE-approaching phase with moderate competitive pressure (30/100), indicating a mature brand facing generic threat and shrinking team resources.
Mechanism of Action
CLINICAL PHARMACOLOGY Bumex is a loop diuretic with a rapid onset and short duration of action. Pharmacological and clinical studies have shown that 1 mg Bumex has a diuretic potency equivalent to approximately 40 mg furosemide. The major site of Bumex action is the ascending limb of the loop of…
Worked on BUMEX at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.